Stockscreener 앱 받기
0.00
100.00%
-15.68
전일 마감가:
$15.68
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$9.35M
수익:
$9.81M
순이익/손실:
$-26.16M
주가수익비율:
0.00
EPS:
-38.77
순현금흐름:
$-17.45M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$18.60
52주 변동 폭
$0.00
$1,212.99
Reshape Lifesciences Inc Stock (RSLS) Company Profile
명칭
Reshape Lifesciences Inc
전화
949-429-6680
주소
1001 CALLE AMANECER, SAN CLEMENTE
RSLS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RSLS
Reshape Lifesciences Inc
|
0.00 | 9.35M | 9.81M | -26.16M | -17.45M | -38.77 |
|
ABT
Abbott Laboratories
|
131.75 | 225.01B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.17 | 154.32B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.91 | 144.71B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
93.02 | 117.85B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.26 | 45.90B | 5.69B | 1.41B | 577.90M | 6.95 |
Reshape Lifesciences Inc 주식(RSLS)의 최신 뉴스
Will ReShape Lifesciences Inc. outperform tech stocksJuly 2025 Outlook & Reliable Breakout Stock Forecasts - classian.co.kr
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update - MarketScreener
ReShape Lifesciences Stock Rocketed 37% Today – Here’s Why - MSN
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update - MarketScreener
How to manage a losing position in ReShape Lifesciences Inc.2025 Historical Comparison & Fast Gain Stock Trading Tips - Newser
Heatmap analysis for ReShape Lifesciences Inc. and competitorsWeekly Gains Summary & Long-Term Capital Growth Ideas - Newser
ReShape Lifesciences Inc. stock prediction for this weekJuly 2025 Weekly Recap & Reliable Volume Spike Trade Alerts - Newser
Real time social sentiment graph for ReShape Lifesciences Inc.Weekly Profit Recap & Free Safe Entry Trade Signal Reports - Newser
ReShape Lifesciences Inc. stock chart pattern explainedWeekly Trade Analysis & Fast Exit and Entry Strategy Plans - Newser
Will ReShape Lifesciences Inc. rebound enough to break evenJuly 2025 Closing Moves & Long-Term Capital Growth Strategies - Newser
Real time pattern detection on ReShape Lifesciences Inc. stockWeekly Profit Summary & Low Risk High Win Rate Picks - Newser
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND - MarketScreener
Vyome Holdings, Inc. shares fall 15.75% premarket after completing merger with ReShape Lifesciences. - AInvest
Vyome Therapeutics Completes Merger with ReShape Lifesciences; Nasdaq Debut Under Ticker HIND - Sahyadri Startups
Vyome Holdings, Inc. shares fall 8.93% premarket after closing merger transaction with ReShape Lifesciences Inc. - AInvest
Vyome Therapeutics' Strategic Merger with ReShape Lifesciences: A Launchpad for US-India Biotech Synergy - AInvest
Chart overlay techniques for tracking ReShape Lifesciences Inc.Weekly Trend Summary & AI Powered Market Trend Analysis - Newser
Why ReShape Lifesciences Inc. stock attracts strong analyst attentionTrade Exit Summary & Low Risk Profit Maximizing Plans - Newser
Vyome Therapeutics Completes Merger with ReShape Lifesciences - AInvest
Vyome Therapeutics Completes Merger With ReShape Lifesciences - MarketScreener
Reshape Lifesciences Reports Q2 2025 Financial Results - TipRanks
Vyome Completes Merger with ReShape Lifesciences, Set to Trade on Nasdaq as HIND - AInvest
Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow - The Globe and Mail
ReShape Lifesciences Inc. SEC 10-Q Report - TradingView
ReShape Lifesciences (RSLS.O) Surges 28.4%: Is It a Short Squeeze or a New Narrative? - AInvest
ReShape Lifesciences Skyrockets 25.47%—What’s Fueling This Pre-Market Surge? - AInvest
Vyome To Begin Trading On Nasdaq Via Reverse Merger With ReShape Lifesciences Tomorrow - Nasdaq
Riding the Waves: A Guide to Investing in RSLS Stock - investchronicle.com
ReShape Lifesciences Surges 31% on Nasdaq Merger Approval: A New Era for Vyome Holdings? - AInvest
Why Did ReShape Lifesciences Plunge 8.75% Amid Vyome Merger? - AInvest
ReShape Lifesciences Stock Scheduled to Reverse Split on Monday, August 18th (NASDAQ:RSLS) - Defense World
ReShape Lifesciences Approves Asset Sale and Merger - TipRanks
Vyome Therapeutics Inc. completed the acquisition of ReShape Lifesciences Inc. in a reverse merger transaction. - MarketScreener
Health Care Stocks Climb As Deals And Results Grab Attention - Finimize
ReShape Lifesciences Soars 66.99% on Nasdaq Merger Approval: A Biotech Merger Sparking Market Frenzy - AInvest
ReShape Lifesciences' Merger With Vyome Therapeutics Receives Nasdaq Approval for Listing - MarketScreener
ReShape Lifesciences Stock Rocketed 37% Today – Here’s Why By Stocktwits - Investing.com India
Vyome announces Nasdaq approval of merger with ReShape Lifesciences - TipRanks
Vyome Therapeutics Announces Nasdaq Approval for Merger with ReShape Lifesciences - AInvest
Recovery Setup Building in ReShape Lifesciences Inc. Experts SayJuly 2025 Opening Moves & Verified Trade Idea Suggestions - sundaytimes.kr
ReShape Lifesciences Stock Rocketed 61% Today – Here’s Why - Stocktwits
Reshape Lifesciences Stock Rocketed 37% Today Here's Why - Menafn
CapsoVision (NASDAQ:CV) versus ReShape Lifesciences (OTCMKTS:RSLSD) Head to Head Comparison - Defense World
Reviewing ReShape Lifesciences (OTCMKTS:RSLSD) and CapsoVision (NASDAQ:CV) - Defense World
Vyome Therapeutics Sets Board To Lead Reshape Lifesciences Post-Close; New Entity To Trade As Vyome Holdings Under Ticker Symbol HIND - 富途牛牛
Vyome Announces New Board of Directors with Deep MIT and AI Ties - The Globe and Mail
How ReShape Lifesciences Inc. stock performs during market volatilityFree Portfolio Optimization Guide - newsyoung.net
ReShape Lifesciences shareholders approve merger with Vyome Therapeutics - MSN
ReShape Lifesciences Approves Asset Sale and Merger with Vyome Therapeutics - AInvest
ReShape Lifesciences RSLS 2025Q2 Earnings Preview Upside Potential on Strategic Reshape Initiatives - AInvest
ReShape Lifesciences Shareholders Approve Merger with Vyome Therapeutics, Ticker Symbol to Change to HIND - AInvest
Reshape Lifesciences Inc (RSLS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.74%
0.24%
자본화:
|
볼륨(24시간):